Tag Archives: STAT News

Humdrum, stodgy Pfizer suddenly turns heads with partial drug-pipeline spinoff; old dog apparently can learn new tricks.

The News: Pfizer Inc. (NYC) on Monday (September 25, 2017) announced that it is spinning off a new company, SpringWorks Therapeutics LLC, to develop several drugs for rare diseases that… Read more »

Novartis gets FDA nod for breakthrough leukemia treatment Kymriah; with a cost of $450,000, who’s going to get it?

The News: Novartis AG (Basel CHE) has obtained approval from the US Food and Drug Administration (FDA) for its Kymriah (tisagenlecleucel or CTL019) to treat children and young adults with… Read more »

Trump’s Exec Order on drug pricing proves he’s like the leopard; he can’t change his spots

A draft of President Donald Trump’s executive order on drug prices lists several proposals to lessen regulatory hurdles for the pharmaceutical industry, reports The New York Times. Here are four things… Read more »

CDC weighs in with new Zika data, heightened warning about complacency

The News: Zika has gradually disappeared from the headlines, buried under the daily avalanche of news coming out of the nation’s capital and terror attacks in Europe. But on Thursday… Read more »

Zika: Forgotten, but not gone; Trump budget would slash funds aimed at safeguarding the public

The News: As the weather gradually gets warmer, and in some areas more humid, public health officials in the United States are quietly gearing up to combat the threat still… Read more »

Senate confirms Gottlieb as FDA chief; former FDA tour, industry ties signal solid choice despite Dems’ jabs

The News: The US Senate voted 57 to 42 on Tuesday (May 9, 2017) to confirm Scott Gottlieb, MD, as Food and Drug Administration (FDA) Commissioner. Gottlieb, who was nominated by… Read more »

NIH proves immune to Trump’s budget scalpel

The News: Lawmakers expanded instead of slashed the budget for the National Institutes of Health (NIH) in its bipartisan deal to fund the government earlier this week, essentially snubbing the… Read more »

Healthcare stocks have rough week as TherapeuticsMD, NantHealth fall flat; but Neurocrine, Tocagen shine

TherapeuticsMD Inc.(NYSE: TXMD) led a large contingent of stocks performing faceplants among the healthcare ranks. The clinical-stage biotech company focused on women’s health, plummeted $2.19, or 28%, to $7.70 in… Read more »

After Trump’s charge of “getting away with murder,” J&J, other Pharmas scramble to tout price restraints; but who’s kidding whom?

Steve’s Take: I thought the pharma business, like any other, was built on the bedrock precept of: charge what the market will bear, until you’re forced to pull back the… Read more »

Broad Institute, UC Berkeley fight CRISPR patent battle for untold $$$; hey IRS: where does nonprofit college end and for-profit business begin?

The News: The US Patent and Trademark Office (USPTO) on Wednesday (February 15, 2017) ruled in favor of the Broad Institute (Cambridge MA) of Harvard University and MIT regarding certain CRISPR-Cas9 patents,… Read more »